ArticleScientific reports2025
A retrospective cohort study of gastrografin in the management of adhesive small bowel obstruction during pregnancy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adhesive small bowel obstruction (ASBO) during pregnancy is a critical condition that remains understudied. This study aimed to address management challenges of ASBO in pregnancy by evaluating the dual diagnostic and therapeutic role of gastrografin. We retrospectively analyzed medical records of pregnant patients with ASBO admitted between September 2018 and September 2023. Patients were categorized into conventional treatment or gastrografin groups based on received therapy. The groups showed no significant differences in demographics, baseline characteristics, or adverse events. However, the gastrografin group demonstrated superior outcomes, including a higher conservative treatment success rate, reduced need for surgery, shorter hospital stays, lower medical costs, and enhanced diagnostic utility. Gastrografin appears relatively safe in pregnancy, with its effective therapeutic action and precise diagnostic capability proving instrumental in managing ASBO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.